secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0000950170-24-106820
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus Therapeutics appoints Steven Romano, M.D. to Board of Directors
------------------------------------------------------------------------

- Appointed Steven Romano, M.D. as Class III director and member of Science & Technology Committee, effective September 16, 2024.
- Initial option grant of 22,000 shares vesting one-third annually over three years.
- Annual cash compensation: $40,000 for board service plus $5,000 for S&T Committee, paid quarterly.
- Dr. Romano will also be eligible for future annual equity grants under the Non-Employee Director Compensation Policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000095017024106820/0000950170-24-106820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000095017024106820/dnth-20240916.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-106820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer